These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 20920851)

  • 1. [Antineoplastic drug-induced neutropenia: use of granulocyte colony stimulating factors].
    Carrato A; Guillén-Ponce C; Grande-Pulido E
    Farm Hosp; 2010 Mar; 34 Suppl 1():8-11. PubMed ID: 20920851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tips on the use of granulocyte colony-stimulating factors in cancer patients predisposed to chemotherapy - induced febrile neutropenia].
    Murakawa Y
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):693-6. PubMed ID: 23863645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.
    Barnes G; Pathak A; Schwartzberg L
    Adv Ther; 2014 Jul; 31(7):683-95. PubMed ID: 24989316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Primary and secondary prophylactic administration of granulocyte-colony stimulating factor(G-CSF)for febrile neutropenia].
    Uchino K; Baba E
    Gan To Kagaku Ryoho; 2014 Jun; 41(6):691-3. PubMed ID: 25129081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
    Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.
    Liang DC
    Paediatr Drugs; 2003; 5(10):673-84. PubMed ID: 14510625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.
    Koinis F; Nintos G; Georgoulias V; Kotsakis A
    Expert Opin Pharmacother; 2015; 16(10):1505-19. PubMed ID: 26077189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
    Ricotta R; Cerea G; Schiavetto I; Maugeri MR; Pedrazzoli P; Siena S
    Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?
    Klastersky J; Awada A; Aoun M; Paesmans M
    Curr Opin Oncol; 2009 Jul; 21(4):297-302. PubMed ID: 19509500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar pegfilgrastim and adherence to guidelines for chemotherapy-induced neutropenia and infections in cancer patients.
    Danova M; Antonuzzo A; Spandonaro F; Pronzato P
    Infez Med; 2020 Mar; 28(1):127-129. PubMed ID: 32172272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia.
    Pérez Velasco R
    J Oncol Pharm Pract; 2011 Sep; 17(3):225-32. PubMed ID: 20562168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to manage neutropenia in multiple myeloma.
    Palumbo A; Bladé J; Boccadoro M; Palladino C; Davies F; Dimopoulos M; Dmoszynska A; Einsele H; Moreau P; Sezer O; Spencer A; Sonneveld P; San Miguel J
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):5-11. PubMed ID: 22178143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?
    Adams JR; Angelotta C; Bennett CL
    J Clin Oncol; 2006 Jul; 24(19):2975-7. PubMed ID: 16682722
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF; Krailo M; Chen Z; Feusner J
    Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.
    Danova M; Barni S; Del Mastro L; Danesi R; Pappagallo GL
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1303-13. PubMed ID: 21916584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.
    Crawford J
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):22-8. PubMed ID: 16736985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.
    Crea F; Giovannetti E; Zinzani PL; Danesi R
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):21-44. PubMed ID: 19111474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.